https://www.fiercebiotech.com/biotech/amyloidosis-biotech-attralus-scores-116m-funding-to-move-into-clinical-trial-stage
Amyloidosis biotech Attralus scores $116M for handful of treatments, imaging agent | Fierce Biotech
Sep 8, 2021 - Attralus Therapeutics has scored $116 million to bring a handful of amyloidosis therapies into the clinic along with an accompanying radiotracer diagnostic...
https://attralus.com/
Novel Pan-Amyloid Removal (PAR) Therapeutics | Attralus
Jan 12, 2026 - Our mission is to improve the lives of amyloidosis patients by developing transformational therapeutics focused on amyloid removal.
novelpanamyloidremovalpar
https://www.nasdaqprivatemarket.com/company/attralus/
Sell or Invest in Attralus Stock Pre-IPO
Apr 15, 2026 - Get started to view information about Attralus stock. Explore insights and opportunities to sell or invest in Attralus shares pre-ipo.
invest insellstockpreipo